Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug

 Drug major Natco Pharma on Friday said its marketing partner Breckenridge Pharmaceutical has received final approval from the US health regulator for Pomalidomide Capsules, treatment of patients suffering from multiple myeloma cancer.

"Breckenridge Pharmaceutical Inc. has received final approval for its abbreviated new drug application (ANDA) for Pomalidomide Capsules from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing.

In addition, Natco and Breckenridge have settled the patent litigation with Celgene (now part of Bristol-Myers Squibb) in the US district court for this product, the company added.

The company, however, did not share details of the settlement.

Celgene sells Pomalidomide Capsules under Brand name Pomalyst in the USA market which is indicated for the treatment of patients suffering from multiple myeloma cancer.

Natco Pharma said as per industry sales data, Pomalyst had annual sales of USD 957 million during the twelve months ending September 2020.

Shares of Natco Pharma were trading 0.50 per cent higher at Rs 910.40 apiece on BSE.

Natco Pharma Q2 net profit rises 73% to Rs 204 crore on robust sales

 Drug firm Natco Pharma on Thursday reported a 73.23 per cent increase in its consolidated net profit to Rs 203.9 crore for the quarter ended September mainly on account of robust sales.

The company had posted a net profit of Rs 117.7 crore for the corresponding period of the previous fiscal, Natco Pharma said in a BSE filing.

Consolidated total income of the company stood at Rs 827.9 crore for the quarter under consideration. It was Rs 518.9 crore for the same period a year ago, it added.

The board of directors has recommended a second interim dividend of Rs 3 per equity share of Rs 2 each for the financial year 2020-21, the filing said.

Shares of Natco Pharma were trading at Rs 902.00 per scrip on BSE, up 0.52 per cent from its previous close.

USFDA completes Chennai facility audit with zero observations: Natco Pharma

Natco Pharma on Monday said the US health regulator has completed the inspection of its Chennai facility, and it ended with zero observations.

In a regulatory filing, Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Chennai, India, conducted during the period July 8-12, 2019".

"The regulatory audit resulted in zero observations," the company added.

Shares of Natco Pharma were trading 0.35 per cent higher at Rs 529.95 apiece on BSE.